ArticleClinical Medicine Insights. Oncology2026

Clinical Outcomes of Lenvatinib-Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort.

Aslı Geçgel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.